CAR T cells beyond cancer: hope for immunomodulatory therapy of infectious diseases
Please always quote using this URN: urn:nbn:de:bvb:20-opus-195596
- Infectious diseases are still a significant cause of morbidity and mortality worldwide. Despite the progress in drug development, the occurrence of microbial resistance is still a significant concern. Alternative therapeutic strategies are required for non-responding or relapsing patients. Chimeric antigen receptor (CAR) T cells has revolutionized cancer immunotherapy, providing a potential therapeutic option for patients who are unresponsive to standard treatments. Recently two CAR T cell therapies, Yescarta® (Kite Pharma/Gilead) and Kymriah®Infectious diseases are still a significant cause of morbidity and mortality worldwide. Despite the progress in drug development, the occurrence of microbial resistance is still a significant concern. Alternative therapeutic strategies are required for non-responding or relapsing patients. Chimeric antigen receptor (CAR) T cells has revolutionized cancer immunotherapy, providing a potential therapeutic option for patients who are unresponsive to standard treatments. Recently two CAR T cell therapies, Yescarta® (Kite Pharma/Gilead) and Kymriah® (Novartis) were approved by the FDA for the treatments of certain types of non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia, respectively. The success of adoptive CAR T cell therapy for cancer has inspired researchers to develop CARs for the treatment of infectious diseases. Here, we review the main achievements in CAR T cell therapy targeting viral infections, including Human Immunodeficiency Virus, Hepatitis C Virus, Hepatitis B Virus, Human Cytomegalovirus, and opportunistic fungal infections such as invasive aspergillosis.…
Author: | Michelle Seif, Hermann Einsele, Jürgen Löffler |
---|---|
URN: | urn:nbn:de:bvb:20-opus-195596 |
Document Type: | Journal article |
Faculties: | Medizinische Fakultät / Medizinische Klinik und Poliklinik II |
Language: | English |
Parent Title (English): | Frontiers in Immunology |
ISSN: | 1664-3224 |
Year of Completion: | 2019 |
Volume: | 10 |
Issue: | 2711 |
DOI: | https://doi.org/10.3389/fimmu.2019.02711 |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Tag: | CAR T cells; CMV; HBV; HCV; HIV; infectious diseases; invasive aspergillosis; mAb engineering |
Release Date: | 2020/08/18 |
Date of first Publication: | 2019/11/21 |
Licence (German): | CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International |